高级搜索

培美曲塞联合含铂方案化疗对非小细胞肺癌患者外周血淋巴细胞表型的影响

王蓉, 张锦英, 刘平, 殷咏梅, 郭人花, 卢凯华, 顾艳宏, 刘连科, 朱陵君

王蓉, 张锦英, 刘平, 殷咏梅, 郭人花, 卢凯华, 顾艳宏, 刘连科, 朱陵君. 培美曲塞联合含铂方案化疗对非小细胞肺癌患者外周血淋巴细胞表型的影响[J]. 肿瘤防治研究, 2012, 39(12): 1464-1468. DOI: 10.3971/j.issn.1000-8578.2012.12.014
引用本文: 王蓉, 张锦英, 刘平, 殷咏梅, 郭人花, 卢凯华, 顾艳宏, 刘连科, 朱陵君. 培美曲塞联合含铂方案化疗对非小细胞肺癌患者外周血淋巴细胞表型的影响[J]. 肿瘤防治研究, 2012, 39(12): 1464-1468. DOI: 10.3971/j.issn.1000-8578.2012.12.014
Wang Rong, Zhang Jinying, Liu Ping, Yin Yongmei, Guo Renhua, Lu Kaihua, Gu Yanhong, Liu Lianke, Zhu Lingjun. Effects of Radiation Therapy Based on Pemetrexed Combination with Cisplation or Carboplatin Regimen on Peripheral Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(12): 1464-1468. DOI: 10.3971/j.issn.1000-8578.2012.12.014
Citation: Wang Rong, Zhang Jinying, Liu Ping, Yin Yongmei, Guo Renhua, Lu Kaihua, Gu Yanhong, Liu Lianke, Zhu Lingjun. Effects of Radiation Therapy Based on Pemetrexed Combination with Cisplation or Carboplatin Regimen on Peripheral Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(12): 1464-1468. DOI: 10.3971/j.issn.1000-8578.2012.12.014

培美曲塞联合含铂方案化疗对非小细胞肺癌患者外周血淋巴细胞表型的影响

基金项目: 江苏省博士后基金资助项目(2010);江苏高校优势学科建设工程资助项目(JX10231801);南京医科大学第一附属医院“创新团队工程”资助项目
详细信息
    作者简介:

    王蓉(1979-),女,硕士,主治医师,主要从事恶性肿瘤临床化疗工作

    通讯作者:

    朱陵君,E-mail:zhulingjun@yahoo.com.cn

  • 中图分类号: R734.2

Effects of Radiation Therapy Based on Pemetrexed Combination with Cisplation or Carboplatin Regimen on Peripheral Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer

  • 摘要: 目的 探讨培美曲塞(pemetrexed)联合顺铂(cisplatin)或卡铂(carboplatin)治疗方案对非小细胞肺癌患者外周血淋巴细胞表型的影响。方法45例经病理学或细胞学确诊的非小细胞肺癌患者,采用培美曲塞500 mg/m2,第1天静脉滴注;顺铂25 mg/m2,第1~3天或卡铂按AUC=5计算剂量,第2天静脉滴注,21天为一周期,毎例患者至少治疗2周期,有可测量病灶者进行疗效评价。应用流式细胞仪检测化疗前和化疗后第7天外周血CD3+、CD4+、CD8+、CD16+56+、CD19+细胞的百分率和CD4+/CD8+比值。结果非小细胞肺癌患者经培美曲塞联合含铂方案化疗后CD4+、CD4+/CD8+、CD16+56+较化疗前升高(P=0.032),CD3+、CD8+、CD19+化疗前后差异无统计学意义(P>0.05);临床分期为ⅢB~Ⅳ期的患者化疗前CD3+、CD4+、CD4+/CD8+和CD16+56+较ⅠB~ⅢA期患者低(P=0.029),化疗后两者比较差异无统计学意义(P>0.05);化疗有效者CD3+、CD4+、CD4+/CD8+比值均显著增高(P=0.008)。结论非小细胞肺癌患者,尤其是晚期患者机体免疫功能低下。培美曲塞联合含铂方案化疗打破了原有的抗肿瘤免疫抑制状态,机体有可能通过免疫重建增强抗肿瘤免疫应答。

     

    Abstract: Objective To evaluate effects of radiation therapy based on pemetrexed combination with cisplatin or carboplatin regimen on the peripheral lymphocyte subsets in patients with non-small cell lung cancer(NSCLC). Methods A total of forty-five patients with a pathologic diagnosis enrolled in this study were treated with pemetrexed 500 mg/m2 infusion on day 1 and cisplatin 25 mg/m2 infusion on day 1 to 3 or carboplatin area under the curve(AUC)5 infusion on day 2.The peripheral blood was collected before and five days after chemotherapy.Every patient must be evaluated with the flow cytometry for CD3+,CD4+,CD8+,CD4+/CD8+,CD16+56+ and CD19+. Results The expressive rates of CD4+,CD16+56+ and CD4+/CD8+ in peripheral blood in post-treatment patients were higher than that in pre-treatment samples (P=0.032).No evident case of changes of CD3+,CD8+,and CD19+ positive cell percentage were observed after chemotherapy(P>0.05).Before chemotherapy,the positive percentage of CD3+,CD4+,CD16+56+ and the ratio of CD4+/CD8+ in NSCLC ⅢB~Ⅳ clinical stage were statistically significantly lower than those in ⅠB~ⅢA clinical stage patients(P=0.029),but were not different from those after chemotherapy(P>0.05).CD3+,CD4+ and the ratio of CD4+/CD8+ in the effective group were highter than those in pre-treatment samples(P=0.008). Conclusion The immune function of advanced stage NSCLC patients is evidently suppressed.Pemetrexed combination with cisplatin or carboplatin regimen for NSCLC may break up anti-tumor immune suppression,then a transient immune suppression condition is reversed by the body rebuilding to enhance the immune function.

     

  • [1] Huang X,Chen LB.Immunomodulatory features of chemotherapeutics[J].Yi Xue Yan Jiu Sheng Xue Bao,2010,23 (1):76-81.[黄香,陈龙邦.化疗药物的免疫调节作用[J].医学研究生学报,2010,23(1):76-81.]
    [2] Chu Y,Wang LX,Yang G,et al .Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma [J].J Immunother,2006,29(4):367 -80.
    [3] Metro G,Chiari R,Mare M,et al.Carboplatin plus pemetrexed for platinum-pretreated,advanced non-small cell lung cancer:a retrospective study with pharmacogenetic evaluation[J].Cancer Chemother Pharmacol,2011,68(6): 1405-12.
    [4] Kim HS,Lee GW,Kim GH,et al.A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer[J].Lung Cancer,2010,70(1):71-6.
    [5] Zhang H,Feng WN,Deng YM,et al.Efficacy of pemetrexed plus cisplatin on chemotherapy-naive patients with advanced nonsquamous non- small cell lung cancer [J].Zhong Liu Fang Zhi Yan Jiu,2012,39(1):88-90. [张华,冯卫能,邓燕明,等.培美曲塞联合顺铂一线治疗晚期非鳞状非小细胞肺癌的疗效观察[J].肿瘤防治研究,2012,39(1) :88-90.]
    [6] Sun Y,Shi YK.Handbook of clinical tumor department of internal medicine[M].Beijing:People′s Medical Publishing House,2007:840-6.[孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2007:840-6.]
    [7] Yang H.Study of the peripheral blood T lymphocyte subsets using flow cytometry in 25 lung cancer patients[J ].Zhongguo Shi Yong Yi Yao,2009,4(26):36-7. [杨红.流式细胞术检测25例肺癌患者T淋巴细胞亚群表型分析[J].中国实用医药,2009,4(26):36-7.]
    [8] Yan X,Zhao X,Jiao SC,et al. Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer[J].Zhongguo Fei Ai Za Zhi,2012,15(3):164-71.[燕翔,赵晓,焦顺昌,等.晚期肺腺癌患者一线化疗后T淋巴细胞亚群变化及临床意义[J]. 中国肺癌杂志,2012,15(3):164-71.]
    [9] Xie ZJ,Xue ZZ,Yang LP.Progress in research of immune reconstitution and its significance after chemotherapy[ J].Zhongguo Quan Ke Yi Xue,2011,14(3):320-2.[谢治军,薛重重,杨丽萍.化疗后肿瘤免疫格局的改变及其意义的研究进展[J].中国全科医学,2011,14(3):320-2.]
    [10] Chu YW,Wen JD,Xiong SD. Changed pattern of tumor immunity under lymphopenia setting and its significance in cancer biotherapy[J].Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi,2007,14(1):7-13.[储以微,温锦娣,熊思东.淋巴 细胞减少状态下的肿瘤免疫格局改变及其意义[J].中国肿瘤生物治疗杂志,2007,14(1):7-13.]
    [11] Mazzoccoli G,Balzanelli M,Giuliani A,et al.Lymphocyte subpopulations anomalies in lung cancer patients and relationship to the stage of disease [J]. In Vivo,1999,13(3):205-9.
    [12] Mo JY,Zhu QY,Zhuang YQ,et al. Effects of neoadjuvant chemotherapy on T-lymphocyte subgroup immunity in patients with advanced breast cancer[J].Shi Yong Ai Zheng Za Zhi,2007,22(5):454-6.[莫军扬,朱其一,庄亚强,等. 新辅助化疗对晚期乳腺癌患者T淋巴细胞亚群免疫功能的影响[J].实用癌症杂志,2007,22(5):454-6.]
    [13] Liu H,Zhang T,Ye J,et al.Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer [J].Cancer Immunol Immunother,2012,61(10):1849-56.
    [14] Luo J,Ling ZQ,Mao WM. Circulating lymphocyte subsets in patients with lung cancer and their prognostic value[J].Zhongguo Fei Ai Za Zhi,2011,14(8):669-73.[罗君,凌志强,毛伟敏.肺癌患者淋巴细胞亚群在外周血中的表达及其与 预后的关系[J].中国肺癌杂志,2011,14(8):669-73.]
计量
  • 文章访问数:  1895
  • HTML全文浏览量:  22
  • PDF下载量:  575
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-09-10
  • 修回日期:  2012-10-07
  • 刊出日期:  2012-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭